Ruconest®
brand of recombinant C1-inhibitor (conestat alpha). Ruconest® is approved by FDA and EMA and is delivered intravenously. Ruconest® is approved for self-administration.
Company: Pharming Group NV
The HAEi Global Access Program enables patients to gain access to Ruconest®–through an ethical and regulatory compliant “Named Patient Program” mechanism–in all countries where the drug is not commercially available.
Global Access Programs provide biopharmaceutical companies with a way to allow ethical access to their pre-license/unlicensed medicines to help patients with unmet medical needs. Access is provided in response to physician requests, in a fully compliant manner, where no alternative treatment options are available.
Key Information
| Ruconest® | |
|---|---|
| Geographical scope | Worldwide excluding territories where Ruconest® is commercially available |
| Pack type | English language pack |
| Order quantity | Minimum of 4 vials. An order of more than 20 vials requires medical review at Pharming |
| Delivery lead time (indication only) | 24-48 hours in EU 48-72 hours outside EU |
How can I get access to Ruconest®?
If you would like to learn more about the Ruconest® through the HAEi Global Access Program, please discuss with your treating physician who should then get in touch with HAEi.
Physician enquiries regarding Ruconest® should be directed by email to: gro.ieah@pag.
Please note that we cannot handle direct patient inquiries.
HAEi Global Access Program Order Process for Ruconest®
